Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 9,997,076 shares of CYTK stock, worth $528 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,997,076
Previous 11,016,889
9.26%
Holding current value
$528 Million
Previous $920 Million
23.8%
% of portfolio
0.01%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding CYTK
# of Institutions
459Shares Held
108MCall Options Held
7.2MPut Options Held
6.2M-
Black Rock Inc. New York, NY12.4MShares$655 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$270 Million0.22% of portfolio
-
Bank Of America Corp Charlotte, NC4.78MShares$252 Million0.03% of portfolio
-
State Street Corp Boston, MA4.52MShares$239 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.98MShares$210 Million0.05% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.97B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...